Literature DB >> 29970392

Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.

Silvia Mele1,2, Stephen Devereux2, Andrea G Pepper2,3, Elvira Infante1, Anne J Ridley1,4.   

Abstract

CD38 is a transmembrane exoenzyme that is associated with poor prognosis in chronic lymphocytic leukemia (CLL). High CD38 levels in CLL cells are linked to increased cell migration, but the molecular basis is unknown. CD38 produces nicotinic acid adenine dinucleotide phosphate and adenosine 5'-diphosphate-ribose, both of which can act to increase intracellular Ca2+ levels. Here we show that CD38 expression increases basal intracellular Ca2+ levels and stimulates CLL cell migration both with and without chemokine stimulation. We find that CD38 acts via intracellular Ca2+ to increase the activity of the Ras family GTPase Rap1, which is in turn regulated by the Ca2+-sensitive Rap1 guanine-nucleotide exchange factor RasGRP2. Both Rap1 and RasGRP2 are required for CLL cell migration, and RasGRP2 is polarized in primary CLL cells with high CD38 levels. These results indicate that CD38 promotes RasGRP2/Rap1-mediated CLL cell adhesion and migration by increasing intracellular Ca2+ levels.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29970392      PMCID: PMC6039665          DOI: 10.1182/bloodadvances.2017014506

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  59 in total

1.  Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Authors:  Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 2.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

3.  Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.

Authors:  Giovanni D'Arena; Michela Tarnani; Carlo Rumi; Tiziana Vaisitti; Semra Aydin; Rosaria De Filippi; Francesco Perrone; Antonio Pinto; Patrizia Chiusolo; Silvia Deaglio; Fabio Malavasi; Luca Laurenti
Journal:  Am J Hematol       Date:  2007-09       Impact factor: 10.047

4.  CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.

Authors:  T Vaisitti; S Aydin; D Rossi; F Cottino; L Bergui; G D'Arena; L Bonello; A L Horenstein; P Brennan; C Pepper; G Gaidano; F Malavasi; S Deaglio
Journal:  Leukemia       Date:  2010-03-11       Impact factor: 11.528

5.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

6.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

Authors:  Julia Hoellenriegel; Sarah A Meadows; Mariela Sivina; William G Wierda; Hagop Kantarjian; Michael J Keating; Neill Giese; Susan O'Brien; Albert Yu; Langdon L Miller; Brian J Lannutti; Jan A Burger
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

Review 7.  The insider's guide to leukocyte integrin signalling and function.

Authors:  Nancy Hogg; Irene Patzak; Frances Willenbrock
Journal:  Nat Rev Immunol       Date:  2011-05-20       Impact factor: 53.106

8.  Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38.

Authors:  M Howard; J C Grimaldi; J F Bazan; F E Lund; L Santos-Argumedo; R M Parkhouse; T F Walseth; H C Lee
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

9.  Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.

Authors:  Sanjay Tiwari; Kyriacos Felekkis; Eun-Yi Moon; Amanda Flies; David H Sherr; Adam Lerner
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

10.  Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity.

Authors:  Santiago Partida-Sánchez; Stephen Goodrich; Kim Kusser; Norman Oppenheimer; Troy D Randall; Frances E Lund
Journal:  Immunity       Date:  2004-03       Impact factor: 31.745

View more
  16 in total

Review 1.  Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.

Authors:  Juanjuan Zhao; Meirong Wu; Zhifeng Li; Sheng Su; Yin Wen; Litian Zhang; Yuhua Li
Journal:  Ann Hematol       Date:  2020-05-09       Impact factor: 3.673

Review 2.  The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.

Authors:  Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-09       Impact factor: 4.249

3.  CD38 Enhances TLR9 Expression and Activates NLRP3 Inflammasome after Porcine Parvovirus Infection.

Authors:  Yi Zheng; Yixuan Xu; Weimin Xu; Sanjie Cao; Qigui Yan; Xiaobo Huang; Yiping Wen; Qin Zhao; Senyan Du; Yifei Lang; Shan Zhao; Rui Wu
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

4.  Intestinal-derived ILCs migrating in lymph increase IFNγ production in response to Salmonella Typhimurium infection.

Authors:  Verena Kästele; Johannes Mayer; Edward S Lee; Natalie Papazian; John J Cole; Vuk Cerovic; Gabrielle Belz; Michio Tomura; Gerard Eberl; Carl Goodyear; Rose A Maciewicz; Daniel Wall; Tom Cupedo; David R Withers; Simon Milling
Journal:  Mucosal Immunol       Date:  2021-01-07       Impact factor: 7.313

Review 5.  Molecular Players in Hematologic Tumor Cell Trafficking.

Authors:  Javier Redondo-Muñoz; Angeles García-Pardo; Joaquin Teixidó
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

Review 6.  Integration of Rap1 and Calcium Signaling.

Authors:  Ramoji Kosuru; Magdalena Chrzanowska
Journal:  Int J Mol Sci       Date:  2020-02-27       Impact factor: 5.923

7.  Construction of a circRNA-miRNA-mRNA Regulatory Network Reveals Potential Mechanism and Treatment Options for Osteosarcoma.

Authors:  Yi He; Haiting Zhou; Wei Wang; Haoran Xu; Hao Cheng
Journal:  Front Genet       Date:  2021-05-17       Impact factor: 4.599

8.  Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility.

Authors:  Junke Wang; Alyssa I Clay-Gilmour; Ezgi Karaesmen; Abbas Rizvi; Qianqian Zhu; Li Yan; Leah Preus; Song Liu; Yiwen Wang; Elizabeth Griffiths; Daniel O Stram; Loreall Pooler; Xin Sheng; Christopher Haiman; David Van Den Berg; Amy Webb; Guy Brock; Stephen Spellman; Marcelo Pasquini; Philip McCarthy; James Allan; Friedrich Stölzel; Kenan Onel; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Front Genet       Date:  2021-06-17       Impact factor: 4.599

Review 9.  The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy.

Authors:  Eleonora Calabretta; Carmelo Carlo-Stella
Journal:  Cells       Date:  2020-03-26       Impact factor: 6.600

Review 10.  RasGRP2 Structure, Function and Genetic Variants in Platelet Pathophysiology.

Authors:  Matthias Canault; Marie-Christine Alessi
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.